MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13195-017-0275-5

Медицинская библиотека · Alzheimer's research & therapy · 2017

No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis.

Goossens Joery, Bjerke Maria, Struyfs Hanne, Niemantsverdriet Ellis, Somers Charisse, Van den Bossche Tobi, Van Mossevelde Sara, De Vil Bart, Sieben Anne, Martin Jean-Jacques, Cras Patrick, Goeman Johan, De Deyn Peter Paul, Van Broeckhoven Christine, van der Zee Julie, Engelborghs Sebastiaan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers Aβ1-42, t-tau, and p-tau181 overlap with other diseases. New tau modifications or epitopes, such as the non-phosphorylated tau fraction (p-taurel), may improve differential dementia diagnosis. The goal of this study is to investigate if p-taurel can improve the diagnostic performance of the AD CSF biomarker panel for differential dementia diagnosis.

METHODS

The study population consisted of 45 AD, 45 frontotemporal lobar degeneration (FTLD), 45 dementia with Lewy bodies (DLB), and 21 Creutzfeldt-Jakob disease (CJD) patients, and 20 cognitively healthy controls. A substantial subset of the patients was pathology-confirmed. CSF levels of Aβ1-42, t-tau, p-tau181, and p-taurel were determined with commercially available single-analyte enzyme-linked immunosorbent assay (ELISA) kits. Diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analyses, and area under the curve (AUC) values were compared using DeLong tests.

RESULTS

The diagnostic performance of single markers as well as biomarker ratios was determined for each pairwise comparison of different dementia groups and controls. The addition of p-taurel to the AD biomarker panel decreased its diagnostic performance when discriminating non-AD, FTLD, and DLB from AD. As a single marker, p-taurel increased the diagnostic performance for CJD. No significant difference was found in AUC values with the addition of p-taurel when differentiating between AD or non-AD dementias and controls.

CONCLUSIONS

The addition of p-taurel to the AD CSF biomarker panel failed to improve differentiation between AD and non-AD dementias.

Для цитирования: Goossens Joery, Bjerke Maria, Struyfs Hanne, Niemantsverdriet Ellis, Somers Charisse, Van den Bossche Tobi, Van Mossevelde Sara, De Vil Bart, Sieben Anne, Martin Jean-Jacques, Cras Patrick, Goeman Johan, De Deyn Peter Paul, Van Broeckhoven Christine, van der Zee Julie, Engelborghs Sebastiaan. No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis.. Alzheimer's research & therapy. 2017. DOI: 10.1186/s13195-017-0275-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.